General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Fixed-income securities information

EUR fixed-income securities

Issuer Amount
(in millions)
Coupon Maturity
Novartis Finance S.A. 1,500 4.250% 2016
Novartis Finance S.A. 600 0.750% 2021
Novartis Finance S.A. 600 1.625% 2026

Credit ratings of Novartis AG

Moody's Standard & Poor's Fitch
Short term P-1 A-1+ F1+
Long term Aa3 AA- AA
Outlook Stable Stable Stable

Novartis Finance S.A.

Principal amount EUR 1,500,000,000
ISIN XS0432810116
Issuer Novartis Finance S.A., Luxembourg
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 4.250%
Coupon payment date June 15
Documentation EMTN Programme
First settlement date June 15, 2009
Issue price 99.757
Maturity date June 15, 2016
Joint book-runners Barclays, BNP Paribas, Deutsche Bank
Bloomberg NOVNVX 4.25 06/15/16
Listing London Stock Exchange

Novartis Finance S.A.

Principal amount EUR 600,000,000
ISIN XS1134758116
Issuer Novartis Finance S.A., Luxembourg
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 0.750%
Coupon payment date November 09
Documentation Standalone
First settlement date November 07, 2014
Issue price 99.134
Maturity date November 09, 2021
Joint book-runners Barclays, BNP Paribas, Deutsche Bank
Bloomberg NOVNVX 0.75 11/09/21
Listing SIX Swiss Exchange

Novartis Finance S.A.

Principal amount EUR 600,000,000
ISIN XS1134729794
Issuer Novartis Finance S.A., Luxembourg
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 1.625%
Coupon payment date November 09
Documentation Standalone
First settlement date November 07, 2014
Issue price 99.697
Maturity date November 09, 2026
Joint book-runners Barclays, BNP Paribas, Deutsche Bank
Bloomberg NOVNVX 1.625 11/09/26
Listing SIX Swiss Exchange

The information provided on this website does not constitute investment advice, or an offer of, or an invitation by, or on behalf of, Novartis AG or any of its subsidiaries, to subscribe for, purchase or sell any securities, including any of the securities described above and below. The information provided also does not constitute an offer, and may not be used for the purpose of an offer to, or a solicitation by, anyone in any jurisdiction or in any circumstances in which such an offer or solicitation is not authorized or is unlawful. You should always seek advice whether governing law permits the use or possession of the information provided.

Neither Novartis AG, nor any of its subsidiaries or employees accepts any liability for any direct or consequential loss arising from any use of the information provided. In particular, neither Novartis AG, nor any of its subsidiaries or employees accepts any liability for any third party content that may be viewed on this site. All information provided is also qualified in its entirety by reference to the relevant prospectuses, supplemental information or other documentation related to the securities described above and below.

Stock chart